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Objectives This study aims to report a “real-world” experience of in hospital complications and clin-
ical outcome of a large cohort of consecutive patients who underwent percutaneous coronary inter-
vention (PCI) with intra-aortic balloon pump counterpulsation (IABP) support, from a tertiary care
center over a 12-year period.
Background The incidence of vascular complications in patients treated with PCI and IABP is ex-
pected to be higher due to simultaneous puncture of femoral arteries, larger IABP sheath size, and
longer duration of IABP therapy.
Methods A total of 360 consecutive patients (mean age of 65.9  11.2 years; 80.6% male) who re-
quired an IABP support during percutaneous PCI were classiﬁed into 3 groups: Urgent: 133 patients
(36.9%) admitted with acute coronary syndrome in whom IABP therapy was started before urgent
PCI; Emergent: 56 patients (15.6%) in whom emergent IABP insertion was required to manage hypo-
tension during PCI; and Elective: 171 patients (47.5%) with stable angina pectoris in whom IABP was
inserted before elective PCI. Overall bleeding was deﬁned according to the newest the Bleeding Ac-
ademic Research Consortium (BARC) deﬁnition criteria.
Results BARC bleeding occurred in 68 patients (19%), with the highest incidence noted in the Ur-
gent group (31.1%), in comparison with the Emergent (26.8%) and Elective (7%) groups, p  0.0001.
leeding related to the IABP access site was 7.5%, which accounted for 82% of any access site–
elated bleeding. It was signiﬁcantly higher in the Urgent group (12.8%) compared with the Elective
4.1%) and Emergent (5.4%) groups. At multivariate analysis, IABP treatment duration and renal im-
airment were the only independent predictors of BARC bleeding.
onclusions Bleeding related to the IABP access site was signiﬁcantly higher in the Urgent group
nd accounted for more than two-thirds of overall access site–related bleeding. IABP treatment du-
ation and renal impairment were independent predictors of overall bleeding. (J Am Coll Cardiol
ntv 2012;5:350–7) © 2012 by the American College of Cardiology Foundation
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351Since the introduction of the intra-aortic balloon pump
(IABP) in 1968 (1) to provide hemodynamic stability for
the critically ill patient, a large volume of data has been
published. In current practice, IABP support is most often
required in the following clinical scenarios: 1) to provide
hemodynamic support in patients admitted with cardiogenic
shock (2); 2) in case of unexpected hypotension during
complex percutaneous coronary intervention (PCI); and
3) electively to prevent hemodynamic deterioration during
complex and high-risk PCI.
However, despite recent advances in revascularization
therapy, medical therapy, and mechanical support with an
IABP, in-hospital mortality rates remain high in patients
with cardiogenic shock (3). The incremental increase in
bleeding complications was reported to be about 3.9% in
patients with acute coronary syndrome, 6.7% if glycoprotein
(GP) IIb/IIIa inhibitors were used, and 18.2% when IABP
was inserted (4). The incidence of vascular complications in
patients treated with PCI and IABP is expected to be higher
due to simultaneous puncture of femoral arteries, larger
IABP sheath size, and longer duration of IABP therapy
(5,6). In addition, IABP therapy during and after PCI
requires the concomitant administration of antithrombin and
antiplatelet agents, which increases the risk of bleeding in an
already high-risk patient population. Recently, it has been
reported that prophylactic usage of an IABP before high-risk
PCI confers no advantage, and should be reserved only for
cases associated with acute hemodynamic deterioration (7).
e aim to report a “real-world” experience of in-hospital
omplications and clinical outcomes of a large cohort of
onsecutive patients who underwent PCI with IABP, from
tertiary care center over a 12-year period.
ethods
Study population. A retrospective analysis of the consecu-
ive patients’ case files of those requiring IABP support
uring PCI in the last 12 years in the Interventional
ardiology Unit of San Raffaele hospital in Milan was
erformed. Patients were classified into 3 groups according
o the indication for IABP insertion: Urgent group: IABP
reatment was started before urgent PCI in patients admit-
ed with acute coronary syndrome; Emergent group: IABP
nserted during PCI to manage hemodynamic acute deteri-
ration; Elective group: IABP inserted before elective high-
isk PCI in patients with stable angina pectoris (e.g., left
ain or multivessel disease PCI in patients with low
jection fraction, PCI in a single remaining vessel, and so
n). IABP insertion was performed in the catheterization
aboratory by an experienced interventional cardiologist. In
ach case, an 8-F IABP catheter (Datascope Corporation,
airfield, New Jersey) was placed percutaneously from a
emoral artery. When IABP was placed after PCI through
he same access site, patients were excluded from the final Knalysis. Balloon counterpulsation was either initiated be-
ore or during PCI. The duration of IABP treatment after
CI was dependent on hemodynamic stability, and removal
as at the discretion of the physician.
All patients received anticoagulation therapy during the
CI procedure, and subsequent therapy was determined by
he clinical status and physician discretion. Most patients
98.3%) received dual antiplatelet therapy (aspirin 325
g/day and either the thienopyridine ticlopidine 250 mg
wice a day, or clopidogrel 300- or 600-mg loading dose
ollowed by 75 mg/day as maintenance therapy).
Study endpoints. The study endpoints were the incidence of
in-hospital complications, such as: 1) bleeding and limb
ischemia; 2) death from any cause; and 3) a combined
endpoint of complications 1 and 2.
Deﬁnitions. Death from any cause was defined as any
n-hospital death during treatment with, or after, removal of
he IABP. Cardiogenic shock was defined as a systolic blood
ressure lower than 90 mm Hg secondary to cardiac dysfunc-
ion with the clinical signs of hy-
operfusion (oliguria, cold ex-
remities, altered mental status).
cute coronary syndrome was
efined as unstable angina pectoris
r acute myocardial infarction (ST-
egment elevation myocardial in-
arction or non–ST-segment eleva-
ion myocardial infarction as
efined by an elevation in serum
reatine kinase of 3 times the
pper limit of the normal laboratory
alue).
Overall bleeding was defined
ccording to the newest Bleed-
ng Academic Research Consor-
ium (BARC) definition criteria (8). Bleeding was then
lassified as access site or nonaccess site bleeding. Bleeding
t the access site was defined by the presence of hemorrhage
t the femoral artery puncture site either for IABP or for
CI; nonaccess site bleeding was defined as the presence of
lesion in the gastrointestinal, genitourinary tract (e.g.,
tomach ulcer, melena, macrohematuria), or where the cause
ould not be identified. Limb ischemia was defined as
hrombosis associated with IABP treatment, requiring re-
oval of the IABP and surgical intervention. The combined
ndpoint included a composite of death, bleeding, and limb
schemia. All events were recorded from baseline (the day of
ABP insertion) until discharge from the hospital.
Statistical analysis. Continuous results are reported as mean 
D or as the median and interquartile range (IQR) (range
rom 25th to the 75th percentile) where appropriate. Cat-
gorical data are presented as counts and percentages. The
Abbreviations
and Acronyms
BARC  Bleeding Academic
Research Consortium
CI  confidence interval
EF  ejection fraction
GP  glycoprotein
IABP  intra-aortic balloon
pump
IQR  interquartile range
OR  odds ratio
PCI  percutaneous
coronary interventionolmogorov-Smirnov test was applied to test whether the
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352data were not normally distributed. Demographic, clinical,
and procedural variables were compared between patients
with and without complications using the Student t test,
hi-square, or Fisher exact tests when appropriate. Fisher
xact test was used when any expected cell count was 5
not resulting from missing rows or columns in a larger
able): for parametric data, the 1-way analysis of variance
as used to test the hypothesis that multiple continuous
esults comparison are equal (more than 2 groups analysis).
he Kruskal-Wallis test was used as the nonparametric
lternative to analysis of variance. Levene’s test was used to
est homogeneity of variance, and the Bonferroni test was
erformed as post-hoc range test. Multivariable logistic regres-
Table 1. Baseline Clinical Characteristics
Overall
(n  360)
Urgent
(n 
Age, yrs 65.9 11.2 [30–94] 65.1
Male 290 (80.6) 96 (
Weight, kg 76.4 13.3 73.8
Previous revascularization 128 (35.6) 28 (
Previous myocardial infarction 182 (50.7) 38 (
Previous stroke 25 (7) 11 (
Peripheral vascular disease 79 (22.1) 26 (
Diabetes 126 (35.4) 42 (
Cardiogenic shock 99 (27.5) 99 (
Acute coronary syndrome 143 (39.7) 133 (
Stable angina pectoris 217 (60.3)
Creatinine, mg/dl 1.3 0.96 1.41
Renal impairment* 82 (23.2) 40 (
INR 1.15 0.32 1.27
Hb, g/dl 13.6 1.9 13.3
Ejection fraction, % 37.7 13.2 32.4
Values are mean SD [nterquartile range], n (%), or mean SD. *Renal impairment was defined b
Hb hemoglobin; INR International Normalized Ratio.
Table 2. IABP-Related Procedural Characteristics
Total Population
(N  360)
Ur
(
IABP treatment, h 3.0 (2.0–22.5) 2
Removal of IABP immediately after PCI 179 (49.9) 1
Closure devices 14 (3.9)
Thienopyridine 354 (98.3) 13
GP IIb/IIIa receptor inhibitors 199 (55.3) 9
Heparin 286 (79.4%) 8
Low-molecular-weight heparin 10 (2.8)
Bivalirudin 15 (4.2)
Dicumarol 5 (1.5)
Thrombolytic drug 6 (1.7)
No antithrombin agent 49 (13.6) 3
In-hospital stay, days 5 (2–11)
Values are median (interquartile range) or n (%).GP glycoprotein; IABP intra-aortic balloon pump; PCI percutaneous coronary intervention.ion analysis was performed to assess the independent
ssociation between potential risk factors and occurrence of
verall in-hospital bleeding. Variables that appeared imbal-
nced by univariate analysis in patients with and without
omplications, indicated by p value 0.1 were included in
he multivariable model. To avoid overfitting, the number
f independent variables entered into the final multivari-
ble model was limited to a maximum of 1 for every 10
vents. Results of the logistic regression model are
resented as the odds ratio (OR) and the 95% confidence
nterval (CI). The discrimination and calibration ability
f the final multivariable logistic model was assessed by
eans of the C-statistic and the Hosmer-Lemeshow
Emergent Group
(n  56)
Elective Group
(n  171) p Value
66.5 9.9 66.3 10.7 0.605
45 (80.4) 148 (86.5) 0.011
76.2 13.3 77.6 11.4 0.054
25 (45.5) 73 (42.7) 0.0001
37 (66.1) 106 (62.4) 0.0001
1 (1.8) 13 (7.7) 0.250
10 (17.9) 43 (25.4) 0.375
18 (32.7) 66 (38.6) 0.472
– – –
10 (17.9) – 0.0001
46 (82.1) 171 (100) 0.0001
1.23 0.9 1.23 0.8 0.241
11 (19.6) 31 (18.1) 0.013
1.14 0.33 1.06 0.14 0.0001
13.6 1.8 13.9 1.8 0.022
42.8 12.3 40 13.9 0.0001
m creatinine concentration of1.4 mg/dl.
roup
3)
Emergent Group
(n  56)
Elective Group
(n  171) p Value
8) 9 (2.25–23.75) 2 (2) 0.0001
) 15 (26.8) 150 (87.7) 0.0001
2 (3.6) 12 (7) 0.007
) 55 (98.2) 169 (99.4) 0.451
) 34 (60.7) 70 (40.9) 0.0001
) 43 (76.8) 160 (93.6) 0.0001
) 1 (1.8) 2 (1.2) 0.093
4 (7.1) 7 (4.1) 0.432
1 (1.8) 1 (0.6) 0.441
2 (3.6) — 0.611
) 8 (14.3) 2 (1.2) 0.0001
5.5) 6 (4–12) 3 (2–5) 0.0001Group
133)
12
72.7)
12.7
21.2)
28.8)
8.4)
20)
32)
74.4)
100)
–
1.14
30.2)
0.44
2.1
10.4
y a serugent G
n  13
4 (8–4
4 (10.5
—
0 (97.7
5 (71.4
3 (62.4
7 (29.3
4 (3)
3 (2.3)
4 (3)
9 (29.3
9 (5–1
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353statistic. A 2-sided p value 0.05 was considered signif-
icant. Calculations were performed with SPSS version
16.0 (IBM, Armonk, New York).
Results
Between January 1998 and July 2010, 360 of 18,813
patients who underwent PCI required IABP support
(0.2%). Of these, 133 patients (36.9%) required IABP
insertion for an urgent indication, 56 (15.6%) for an
emergent indication, and the remaining 171 (47.5%) for
an elective indication. Baseline clinical characteristics are
shown in Table 1. Cardiogenic shock was present in most
patients in the Urgent group (74.4%). Renal impairment
and a lower left ventricular ejection fraction (EF) were more
common in the Urgent group (30.2%; EF: 32.4  10.4%,
respectively) than in the Emergent (19.6%; EF: 42.8 
12.3%) and Elective (18.1%; EF: 40  13.9%) groups, p 
Table 3. Clinical Endpoints
Total Population
(N  360)
Urgent Gro
(n  133
Death 46 (12.8) 40 (30.1)
BARC bleeding 68 (19.0) 41 (30.8)
Access site bleeding 33 (9.2) 21 (15.8)
IABP access site bleeding 27 (7.5) 17 (12.8)
PCI access site bleeding 11 (3.1) 6 (4.5)
Nonaccess site bleeding 41 (11.4) 26 (19.5)
Blood transfusion 36 (10.0) 25 (18.8)
Limb ischemia 7 (1.9) 6 (4.5)
Combined endpoint 104 (29.1) 71 (53.4)
Values are n (%).
BARC Bleeding Academic Research Consortium; other abbreviations as in Table 2.
Figure 1. Clinical Outcome*p  0.013, Urgent versus Emergent group; †p  0.046, Urgent versus Elective; and0.013. IABP-related procedural characteristics are shown in
Table 2. IABP treatment duration was significantly longer
in patients with cardiogenic shock in the Urgent group
(median 27 h; IQR: 2 to 472 h) compared with the
Emergent (median 9 h; IQR: 2.25 to 23.75 h) and Elective
(median 2 h; IQR: 2 to 2 h) groups, p  0.0001. In 49
(13.6%) of 360 patients, no antithrombin agent for IABP-
related treatment was given. The high risk of bleeding or
on-going bleeding was a cause to discontinue antithrom-
bin agents in 21 of 49 patients (42.9%): 18 patients
(13.5%) in the Urgent group, 2 (3.6%) in the Emergent
group, and 1 (0.6%) in the Elective group; p  0.0001. A
GP IIb/IIIa receptor inhibitor was used more frequently
in the Urgent group (71.4%) than in the Emergent
(60.7%) or Elective (41%) groups, p  0.0001.
Clinical endpoints. Clinical endpoints are summarized in
Table 3 and Figure 1.
Emergent Group
(n  56)
Elective Group
(n  171) p Value
5 (8.9) 1 (0.6) 0.0001
15 (26.8) 12 (7.0) 0.0001
3 (5.4) 9 (5.3) 0.04
3 (5.4) 7 (4.1) 0.014
1 (1.8) 4 (2.3) 0.461
12 (21.4) 3 (1.8) 0.0001
6 (10.7) 5 (2.9) 0.0001
— 1 (0.6) 0.025
19 (33.9) 14 (8.2) 0.0001up
)‡p  0.001, Emergent versus Elective group.
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354Bleeding events. BARC bleeding occurred in 68 patients
(19%): type 3a bleeding in 37 cases (10.3%); type 3b in 29
(8.1%); type 5a in 1 (0.3%); and type 5b in 1 case (0.3%).
The highest incidence was noted in the Urgent (30.8%) and
Emergent (26.8%) groups compared with the Elective
group (7%), p 0.0001, (Table 3, Fig. 1); 33.3% of patients
with cardiogenic shock had a bleeding complication (33 of
99 patients), which accounted for 80.5% of all bleeding
events in the Urgent group.
Access site–related bleeding was noted in 33 patients
(9.2%): 21 in the Urgent (15.8%), 3 in the Emergent (5.4%),
and 9 in the Elective (5.3%) group (p value reported in
Table 3). Of these 33 patients, pseudoaneurysm at the
access site occurred in 7 patients, 1 of which required acute
surgical intervention. In 1 patient, an arteriovenous fistula
was noted, and elective surgical repair was planned.
IABP access site–related bleeding was noted in 27 pa-
tients (7.5%) and accounted for 82% of overall bleeding at
the access site (Fig. 2). The highest incidence of IABP-
related bleeding occurred in patients in the Urgent group
Figure 2. BARC Bleeding Events Related to the Access and Nonaccess SitBARC  Bleeding Academic Research Consortium; IABP  intra-aortic balloon pump(12.8%) compared with the Elective (4.1%, p  0.005) and
Emergent (5.4%, p  NS) groups (Fig. 3). The lowest
incidence occurred in the Elective group when the IABP
was removed immediately after the PCI procedure (3.5%).
Of the 68 patients with a bleeding complication, 36
required blood transfusion (52.9%). Blood transfusion was
required for bleeding in 69.7% of patients with cardiogenic
shock and in 33.3% in the presence of access site–related
bleeding. The incidence of bleeding at the IABP access site
requiring blood transfusion was 6.8% in the Urgent group
and 1.8% in the Elective group.
All acute vascular thrombosis requiring vascular surgery
occurred at the IABP access site (n  7, 1.9%). Most of
these (85.7%) involved Urgent patients.
Death. Forty-six patients (12.8%) died during the hospital
stay after a median of 5.5 days (IQR: 2 to 16.25 days) (Table
3, Fig. 1). The incidence of death was higher in the Urgent
(30.3%) compared with the Emergent (9.1%) and Elective
(0.6%) groups, p  0.0001. The highest incidence of death
occurred in patients admitted with cardiogenic shockes; PCI  percutaneous coronary intervention.
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355(36.4%). Death caused by complications related to arterial
access occurred in 6 patients (1.7%): acute thrombosis of the
IABP access site artery was noted in 3 patients and of both
iliac arteries in 1 patient; retroperitoneal bleeding caused by
insertion of an extracorporeal membrane oxygenator oc-
curred in 1 patient; amputation of the limb below the knee
occurred at 1 month post-IABP removal in 1 patient. All
these patients presented with cardiogenic shock.
Combined endpoint. The combined endpoint was detected
in 104 patients (29.1%) and was significantly higher in the
Urgent group (53.8%) compared with the Emergent
(34.5%) and Elective (8.2%) groups, p  0.0001.
Predictors of BARC bleeding. Multivariate logistic regression
nalysis (Table 4) revealed that independent predictors of
Figure 3. BARC Bleeding According to Location
*p  0.005, Urgent versus Elective group; †p  0.0001, Emergent versus Elect
Table 4. Predictors of BARC Bleeding
Present
(n  68)
Not Present
(n  292)
Age, yrs 67.2 10.5 65.6 11.3
Male* 49 (72.1) 241 (82.5)
Weight, kg 73.4 11.9 76.7 12.3
Previous myocardial infarction 27 (40.3) 155 (53.1)
Previous revascularization 21 (30.9) 107 (36.6)
Diabetes 20 (29.4) 106 (37)
IABP treatment, h 23.5 (4.6–49.5) 2 (2–15)
Left ventricular ejection fraction, % 35.6 12.7 38.2 13
Urgent group 41 (60.3) 92 (31.5)
Emergent group 15 (22.1) 41 (14)
Elective group 12 (17.6) 159 (54.5)
Hb, g/dl 13.4 2.2 13.7 1.8
Renal impairment 24 (35.3) 58 (20)
GP IIb/IIIa inhibitors 49 (72.1) 150 (51)
Values are mean SD, n (%), or median (interquartile range). On multivariate analysis, the HosmerCI confidence interval; OR odds ratio; other abbreviations as in Tables 1, 2, and 3.ARC bleeding were IABP treatment duration (adjusted
R: 1.015/h; 95% CI: 1.005 to 1.024; p  0.002) and renal
mpairment (adjusted OR: 1.893; 95% CI: 1.004 to 3.573;
 0.049). Having an IABP inserted electively was found
o be a negative predictor of BARC bleeding (adjusted OR:
.273; 95% CI: 0.115 to 0.648; p  0.003).
iscussion
The principal findings of this study are: 1) the incidence of
overall bleeding, limb ischemia, and mortality in patients
requiring IABP support before or during PCI was 19%,
1.9%, and 12.8%, respectively; 2) IABP access site–related
bleeding occurred in 7.5% of patients, with the highest
up. Abbreviations as in Figure 2.
Univariate OR
(95% CI) p Value
Multivariate OR
(95% CI) p Value
1.012 (0.988–1.037) 0.321
0.546 (0.297–1.004) 0.052 0.656 (0.301–1.429) 0.289
0.977 (0.954–1.001) 0.060
0.597 (0.348–1.023) 0.061
0.773 (0.438–1.362) 0.371
0.723 (0.407–1.284) 0.267
1.017 (1.010–1.025) 0.0001 1.010 (1.003–1.018) 0.007
0.985 (0.964–1.007) 0.177
3.301 (1.914–5.693) 0.0001 0.851 (0.406–1.784) 0.669
1.733 (0.894–3.357) 0.100
0.179 (0.092–0.348) 0.0001 0.273 (0.115–0.648) 0.003
0.915 (0.797–1.050) 0.205
2.201 (1.239–3.909) 0.006 1.893 (1.004–3.573) 0.049
2.441 (1.371–4.349) 0.002 1.675 (0.894–3.138) 0.107
ow goodness of fit test p 0.746; C-statistic 0.755. *n 290.-Lemesh
t
o
t
s
9
o
s
r
s
o
i
i
s
w
v
l
c
s
w
p
i
p
h
i
b
H
t
m
t
d
C
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 3 , 2 0 1 2
M A R C H 2 0 1 2 : 3 5 0 – 7
Davidavicius et al.
Bleeding Related to Intra-Aortic Balloon Pump
356incidence noted in the Urgent group (12.8%); 3) the highest
complication rate occurred in the Urgent group (53.4%) and
was mainly driven by the presence of cardiogenic shock; and
4) IABP treatment duration and renal impairment were the
only independent predictors of overall bleeding.
The present study shows that the frequency of overall
bleeding in patients with IABP undergoing PCI was higher
in the presence of acute coronary syndrome (30.8%, Urgent
group) and after emergent IABP placement to treat hypo-
tension occurring during PCI (26.8%). The 30.8% inci-
dence of bleeding in Urgent patients is consistent with
previous reports, which showed overall bleeding rates of
23% to 27% (9–11). However, it is higher than that
reported in the GRACE registry (Global Registry of Acute
Coronary Events), where the incidence of bleeding was only
18.2% in patients with acute coronary syndrome requiring
IABP support (4). This discrepancy may be related to
differences in patient’s clinical characteristics and to the way
in which bleeding was defined. We observed that the
incidence of overall bleeding was significantly higher after
emergency IABP insertion compared with elective insertion
(26.8% vs. 7%, respectively), most likely related to the
greater use of GP IIb/IIIa agents (60.7% vs. 40.9%, respec-
tively) and longer duration of IABP support (median 9 vs.
2 h, respectively). It is also noteworthy that bleeding at
nonaccess sites contributed significantly to this difference
(21.4% at nonaccess sites compared with only 1.8% at access
sites). The fact that the Elective group was a negative
predictor for overall bleeding complications might be ex-
plained by a number of clinical and procedural characteris-
tics: lower usage of GP IIb/IIIa agents; fewer patients with
renal impairment; and the early removal of the IABP
immediately after PCI in 87% of patients. The present study
found 2 significant independent predictors for overall bleed-
ing: 1) renal impairment (OR: 1.893), which again is
consistent with reports in the literature (12); and 2) the
duration of IABP treatment (OR: 1.010). IABP treatment
requires continuous systemic anticoagulation, which can
potentially increase the risk of vascular complications, espe-
cially if required for 48 h (13).
In contrast to the previous data reported by Cohen et al.
(14), we did not find that peripheral vascular disease was an
independent predictor for overall bleeding complications.
This discrepancy is most likely related to differences in
patient selection (50% of our patients were treated for
stable angina instead of myocardial infarction) and in the
definitions used for vascular complications and bleeding
between the 2 studies.
This study provides additional and important informa-
tion on the relationship between IABP use and the risk of
bleeding, in the spectrum of IABP utilization during PCI
procedures. The highest bleeding rate at the IABP access
site occurred in the Urgent group (12.8%) in whom the
median duration of treatment was 24 h. Not surprisingly,the lowest incidence of IABP access site bleeding occurred
in patients in the Elective group (3.5%), where the IABP
was removed immediately after PCI.
In our patient cohort, the occurrence of access site–
related death was low (1.4%). We found that limb ischemia
caused by IABP insertion in the presence of cardiogenic
shock, and requiring surgical intervention, impacted signif-
icantly on hospital survival. Indeed, it has previously been
reported that although limb ischemia following IABP use is
an uncommon complication, occurring with an incidence of
0.5% to 5% (14,15), it has an adverse effect on overall
prognosis (16). Again, consistent with previous reports (12),
he highest incidence of in-hospital death in our study
ccurred in patients with cardiogenic shock (36.4%). Fur-
hermore, the mortality rate in patients with cardiogenic
hock occurring unexpectedly during PCI remains high, at
.1%, in our study. With mortality reported at up to 29% in
ther studies (17), this should be considered a malignant
cenario.
Several important aspects can be considered to reduce the
ate of bleeding complications in patients requiring IABP
upport during PCI procedures. Certainly, the modification
f intraprocedural pharmacotherapy by, for example, replac-
ng unfractionated heparin with newer direct thrombin
nhibitors, such as bivalarudin, and by reducing the exces-
ive, and often unnecessary, use of GP IIb/IIIa inhibitors
ould be an important first step.
In current clinical practice, hemodynamic support pro-
ided by IABP remains effective and competitive with other
eft ventricular assist devices. A previous meta-analysis of
ontrolled trials revealed that in patients with cardiogenic
hock, superior hemodynamic improvement can be achieved
ith percutaneous assist devices than with IABP counter-
ulsation. However, this advantage did not translate into
mproved 30-day survival, and patients treated with a
ercutaneous left ventricular assist device tended to have a
igher incidence of leg ischemia and device-related bleeding
n comparison with IABP (17).
This study is retrospective, single-center analysis; thus,
ias and confounding factors could not be eliminated.
owever, this study reflects a large single-center report on
he “real-world” use of IABP during PCI procedures and
ay be helpful to evaluate the risk of bleeding and highlight
he importance of newer and safer pharmacological and
evice strategies in this cohort of patients.
onclusions
This study shows that in patients who required IABP
support during PCI, bleeding related to IABP access site
occurred in 7.5% of patients and accounted for more than
two-thirds of access site–related bleeding. IABP treatment
duration and the presence of renal impairment were inde-
pendent predictors of overall bleeding.
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